
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>EASL vs AASLD Guidelines on Hepatocellular Carcinoma (HCC)</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>EASL vs AASLD Guidelines on Hepatocellular Carcinoma (HCC)</strong></summary>
            <div>
                <ul><li>- A comparative mind map of the 2024 EASL and 2023 AASLD clinical practice guidelines on HCC management.</li><li>- EASL Source: Journal of Hepatology, Feb 2025, vol. 82, 315–374</li><li>- AASLD Source: Hepatology, 2023, vol. 78, 1922–1965</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the recommended threshold for future liver remnant (FLR) in patients with cirrhosis undergoing resection according to AASLD?</li><li>- What is the 5-year HCC recurrence risk after surgical resection?</li><li>- In the HIMALAYA trial, what was the 36-month survival rate for the Durvalumab + Tremelimumab (STRIDE) regimen?</li><li>- According to EASL, what is the key imaging feature difference between HCC and intrahepatic cholangiocarcinoma on CEUS?</li><li>- What is the RETREAT score used for?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Guideline Comparison: Scope & Key Differences</strong></summary>
            <div>
                <ul><li>- <b>Consensus Areas:</b> Both guidelines endorse <u>BCLC staging</u>, <u>LI-RADS for diagnosis</u>, <u>surveillance for at-risk populations</u> (cirrhosis, high-risk HBV), and <u>combination immunotherapy</u> as first-line systemic therapy.</li><li>- <b>Key Divergences & Scope Differences:</b></li><li>- <u>Adjuvant Therapy:</u> <b>AASLD</b> strongly recommends adjuvant <b>Atezolizumab + Bevacizumab</b> for high-risk patients based on initial IMbrave050 results. <b>EASL</b> is more cautious, noting the RFS benefit was not sustained in later follow-up and does not recommend it.</li><li>- <u>Surveillance Recall:</u> <b>AASLD</b> provides a specific, detailed algorithm for managing surveillance findings (e.g., US-1, US-2, US-3 lesions).</li><li>- <u>Imaging Nuances:</u> <b>EASL</b> offers a more in-depth discussion on the comparative evidence for different imaging modalities (e.g., ECA-MRI vs. HBA-MRI) for diagnosis and staging.</li><li>- <u>Transplant Criteria:</u> <b>AASLD</b> focuses on US-specific criteria (UNOS, MELD, MMaT-3), while <b>EASL</b>'s discussion is more generalized.</li><li>- <u>Advance Care Planning:</u> <b>AASLD</b> includes a dedicated section and guidance statement on Advance Care Planning (ACP).</li><li>- <u>Locoregional Therapy Evidence:</u> <b>EASL</b> provides a more granular review of RCTs comparing different embolization techniques (cTACE vs DEB-TACE vs TAE) and TACE vs SIRT/EBRT.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Prevention & Surveillance</strong></summary>
            <div>
                <ul><li>- Primary prevention focuses on managing underlying liver disease (e.g., cirrhosis) to reduce HCC incidence.</li><li>- Surveillance aims to detect HCC at an early, treatable stage to reduce mortality.</li></ul>
                
        <details>
            <summary><strong>Primary Prevention</strong></summary>
            <div>
                <ul><li>- Focuses on treating underlying causes of liver disease and modifying lifestyle risk factors.</li></ul>
                
        <details>
            <summary><strong>Antiviral Therapy</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Both guidelines strongly recommend antiviral therapy for HBV and HCV to reduce HCC risk.</li></ul>
                
        <details>
            <summary><strong>Hepatitis B (HBV)</strong></summary>
            <div>
                <ul><li>- <b>EASL:</b> NUCs (nucleoside/nucleotide analogues) significantly decrease HCC risk (RR <q>0.48</q>).</li><li>- Recommended NUCs (<u>entecavir</u>, <u>tenofovir</u>) are superior to non-first-line NUCs.</li><li>- Tenofovir may reduce late recurrence risk compared to entecavir (adjusted HR <q>0.58</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Hepatitis C (HCV)</strong></summary>
            <div>
                <ul><li>- <b>EASL:</b> Direct-acting antivirals (DAAs) reduce the risk of cirrhosis and its complications, including HCC.</li><li>- Impact on HCC recurrence after treatment is inconclusive.</li><li>- Benefit of reduced decompensation and improved OS likely outweighs potential recurrence risk.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Lifestyle & Chemoprevention</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Both guidelines recommend lifestyle modifications like alcohol/tobacco cessation and weight management.</li></ul>
                
        <details>
            <summary><strong>Lifestyle Modifications</strong></summary>
            <div>
                <ul><li>- <b>EASL:</b> Recommends <u>alcohol cessation</u>, <u>tobacco cessation</u>, and <u>weight loss</u> in obesity to reduce liver-related adverse outcomes.</li><li>- <b>AASLD:</b> Smoking increases HCC risk by <q>20%-86%</q>, which normalizes after <q>30 years</q> of cessation.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Coffee Consumption</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Both guidelines suggest coffee may be recommended due to observational data showing reduced HCC risk.</li><li>- <b>EASL:</b> Notes a dose-response protective effect, but the effect is much less strong than alcohol/smoking cessation.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Medications (Chemoprevention)</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Both guidelines state there is insufficient evidence to recommend <b>statins</b>, <b>aspirin</b>, or <b>metformin</b> solely for HCC chemoprevention.</li><li>- <b>AASLD:</b> Notes these agents can be used if other indications are present.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Surveillance Strategy</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Surveillance is recommended for patients with cirrhosis and other high-risk groups to improve survival through early detection.</li></ul>
                
        <details>
            <summary><strong>Target Population</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Patients with <u>cirrhosis</u> (Child-Pugh A/B) and certain non-cirrhotic <u>HBV</u> patients are the primary targets.</li></ul>
                
        <details>
            <summary><strong>AASLD View</strong></summary>
            <div>
                <ul><li>- Surveillance recommended for HCC incidence <q>≥1.0% per year</q> in cirrhosis, lower than the traditional <q>1.5%</q>.</li><li>- For non-cirrhotic HBV, recommends surveillance for specific groups (e.g., men from endemic country >40y, family history, PAGE-B score <q>≥10</q>).</li><li>- <u>Not recommended</u> for Child-Pugh C patients not on transplant list or those with life expectancy <q>1-2 years</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>EASL View</strong></summary>
            <div>
                <ul><li>- Recommends surveillance for all patients with cirrhosis who are candidates for curative-intent treatment.</li><li>- Acknowledges emerging risk stratification models (e.g., PAGE-B) to personalize surveillance intensity.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Populations with Insufficient Evidence</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Routine surveillance is <u>not currently recommended</u> for patients with advanced fibrosis (F3) without cirrhosis (e.g., post-SVR HCV, NAFLD) due to low HCC incidence (<q>~0.5 per 100 person-years</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Surveillance Test & Interval</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> The recommended interval is every <b>6 months</b>.</li></ul>
                
        <details>
            <summary><strong>Recommended Test</strong></summary>
            <div>
                <ul><li>- <b>AASLD:</b> Recommends combination of <u>ultrasound (US) + AFP</u>.</li><li>- US alone has sensitivity of <q>53%</q> for early HCC.</li><li>- US + AFP increases sensitivity to <q>63%</q>.</li><li>- <b>EASL:</b> Recommends <u>ultrasound</u> as the primary test.</li><li>- Combined use with AFP is a 'reasonable option' that increases sensitivity but decreases specificity.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Alternative Modalities</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Routine use of CT or MRI for surveillance is <u>not recommended</u> due to cost, radiation (CT), and capacity issues.</li><li>- <b>AASLD:</b> Suggests contrast-enhanced MRI may be considered in patients where US is suboptimal (e.g., obesity, parenchymal heterogeneity).</li><li>- <b>EASL:</b> Notes abbreviated MRI is a promising area of research but awaits results from ongoing trials.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Emerging Biomarkers</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Other biomarkers (DCP, AFP-L3, GALAD score) are promising but not yet recommended for routine surveillance.</li><li>- <b>EASL:</b> GALAD score for early HCC showed sensitivity of <q>73%</q> and specificity of <q>87%</q> in a meta-analysis, but studies had high selection bias.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Recall & Management of Findings (AASLD)</strong></summary>
            <div>
                <ul><li>- AASLD provides a specific algorithm for managing surveillance results.</li></ul>
                
        <details>
            <summary><strong>Negative/Benign Screen</strong></summary>
            <div>
                <ul><li>- US LI-RADS 1 (no lesion) + normal AFP ---> Continue routine <b>6-month surveillance</b>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Sub-centimeter Lesion</strong></summary>
            <div>
                <ul><li>- US LI-RADS 2 (<1 cm lesion) ---> Repeat US + AFP in <q><b>3-6 months</b></q>.</li><li>- If stable on ≥2 follow-up exams, return to routine 6-month surveillance.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Suspicious Findings</strong></summary>
            <div>
                <ul><li>- US LI-RADS 3 (≥1 cm lesion) OR AFP ≥<q>20 ng/ml</q> ---> Proceed to <b>diagnostic multiphasic CT or MRI</b>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Inadequate Visualization</strong></summary>
            <div>
                <ul><li>- US LI-RADS Visualization B (moderate limits) or C (severe limits) ---> Consider alternative imaging like MRI.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnosis & Staging</strong></summary>
            <div>
                <ul><li>- Accurate diagnosis and staging are critical for determining prognosis and guiding therapy.</li><li>- Non-invasive diagnosis is possible in high-risk patients using specific imaging criteria.</li></ul>
                
        <details>
            <summary><strong>Non-Invasive Diagnosis</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Both guidelines endorse the use of <b>LI-RADS</b> to standardize imaging acquisition, interpretation, and reporting for non-invasive HCC diagnosis in at-risk patients (cirrhosis, chronic HBV).</li></ul>
                
        <details>
            <summary><strong>Diagnostic Criteria (LI-RADS)</strong></summary>
            <div>
                <ul><li>- Diagnosis is based on major features: <u>APHE</u> (arterial phase hyperenhancement) and <u>washout</u> (portal venous/delayed phase).</li><li>- Other features include enhancing capsule and threshold growth.</li></ul>
                
        <details>
            <summary><strong>LI-RADS Categories</strong></summary>
            <div>
                <ul><li>- <b>LR-5 (Definitely HCC):</b> Probability of HCC is <q>~95-99%</q>. No biopsy needed for treatment decisions.</li><li>- <b>LR-4 (Probably HCC):</b> Probability of HCC is <q>~75%</q>. Requires biopsy or close imaging follow-up.</li><li>- <b>LR-3 (Intermediate Probability):</b> Probability of HCC is <q>~30%</q>. Requires imaging follow-up in 3-6 months.</li><li>- <b>LR-M (Malignant, not specific for HCC):</b> High probability of malignancy (<q>93-100%</q>), but only <q>29-44%</q> are HCC. <u>Biopsy is mandatory</u>.</li><li>- <b>LR-TIV (Tumor in Vein):</b> Highly specific for HCC.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Choice of Imaging Modality</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Multiphase <b>CT</b> or dynamic contrast-enhanced <b>MRI</b> are the recommended first-line modalities.</li></ul>
                
        <details>
            <summary><strong>CT vs. MRI</strong></summary>
            <div>
                <ul><li>- <b>AASLD:</b> MRI has slightly higher sensitivity than CT (<q>82% vs 66%</q>) with similar specificity. Both are equally recommended.</li><li>- <b>EASL:</b> A prospective trial showed similar sensitivity for MRI (<q>71%</q>) and CT (<q>70%</q>) for nodules 1-3 cm.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>MRI Contrast Agents (ECA vs. HBA)</strong></summary>
            <div>
                <ul><li>- <b>EASL:</b> Recommends <u>extracellular contrast agents (ECA)</u> over hepatobiliary agents (HBA, e.g., gadoxetic acid) for diagnosis.</li><li>- Head-to-head studies show ECA-MRI has higher sensitivity (<q>78% vs 66%</q>) and accuracy (<q>82% vs 73%</q>) for LR-5 diagnosis.</li><li>- HBA-MRI is associated with transient respiratory motion artifacts and may identify APHE in fewer cases.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Contrast-Enhanced Ultrasound (CEUS)</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> CEUS is <u>not a first-line</u> diagnostic tool due to lower sensitivity and inability to stage the whole liver.</li><li>- <b>EASL:</b> Can be used if CT/MRI are inconclusive. Specific criteria for HCC are APHE followed by <u>late (>60s)</u> and <u>mild</u> washout, which helps differentiate from cholangiocarcinoma (often has early, marked washout).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pathological Diagnosis (Biopsy)</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Biopsy is required for diagnosis in patients <u>without</u> cirrhosis or chronic HBV, or for indeterminate nodules (e.g., LR-4, LR-M) in at-risk patients.</li></ul>
                
        <details>
            <summary><strong>Biopsy Utility & Technique</strong></summary>
            <div>
                <ul><li>- <b>AASLD:</b> Biopsy sensitivity is <q>70-93%</q>, but can be as low as <q>~60%</q> for tumors <2 cm.</li><li>- <b>EASL:</b> Recommends percutaneous access under US or CT guidance. Suggests sampling non-tumoral liver to aid diagnosis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Histological & Molecular Analysis</strong></summary>
            <div>
                <ul><li>- <b>EASL:</b> Recommends reporting prognostic features like differentiation grade and WHO subtype (e.g., macrotrabecular/massive, progenitor).</li><li>- A panel of 3 immunostains (<u>glypican-3</u>, <u>glutamine synthetase</u>, <u>HSP70</u>) has <q>100%</q> specificity for HCC.</li><li>- Routine molecular analysis is not yet recommended as it does not currently inform therapeutic decisions.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Staging</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> The <b>BCLC (Barcelona Clinic Liver Cancer)</b> classification is the recommended staging system as it incorporates tumor burden, liver function, and performance status.</li></ul>
                
        <details>
            <summary><strong>Staging Workup</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Initial staging requires contrast-enhanced chest, abdominal, and pelvic scans (CT is often used).</li><li>- Bone scan/brain MRI are not needed unless symptoms are present.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Role of HBA-MRI in Staging</strong></summary>
            <div>
                <ul><li>- <b>EASL:</b> Suggests gadoxetic acid-enhanced MRI (HBA-MRI) for patients who are candidates for curative treatments (resection, ablation, transplant).</li><li>- HBA-MRI has higher sensitivity for detecting small nodules, which may improve local tumor staging and alter treatment plans in up to <q>13.3%</q> of cases.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Role of PET/CT</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> 18F-FDG-PET/CT is <u>not recommended</u> for routine staging due to low sensitivity (<q><40%</q> of HCCs show uptake).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Role of AFP</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> AFP should be measured at diagnosis for prognostic information.</li><li>- An AFP level > <q>400 ng/ml</q> is consistently associated with worse prognosis across all treatment modalities.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Multidisciplinary Team (MDT) Approach</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Both guidelines strongly emphasize that all patients with HCC should be managed by an MDT.</li><li>- <b>AASLD:</b> MDT review can alter imaging interpretation in <q>18.4%</q> of cases and change management plans in <q>41.7%</q> of patients.</li><li>- <b>EASL:</b> MDT should include hepatobiliary/transplant surgeon, medical oncologist/hepatologist, radiation oncologist, interventional/diagnostic radiologist, pathologist, and a dedicated nurse.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>- Treatment decisions are guided by BCLC stage, liver function, and patient factors, requiring an MDT approach.</li></ul>
                
        <details>
            <summary><strong>Surgical Therapies: Resection & Transplantation</strong></summary>
            <div>
                <ul><li>- Surgical interventions are performed with curative intent and include Liver Resection (LR) and Liver Transplantation (LT).</li></ul>
                
        <details>
            <summary><strong>Liver Resection (LR)</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> LR is the treatment of choice for localized HCC in non-cirrhotic patients and in well-selected patients with compensated (Child-Pugh A) cirrhosis.</li></ul>
                
        <details>
            <summary><strong>Patient Selection for LR in Cirrhosis</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Selection requires a multi-parametric assessment to keep perioperative mortality <q><3%</q>.</li><li>- Key factors: liver function (Child-Pugh, ALBI), portal hypertension, and future liver remnant (FLR) volume.</li><li>- <b>AASLD:</b> Recommends FLR > <q>40%</q> in patients with cirrhosis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Contraindications to LR</strong></summary>
            <div>
                <ul><li>- <b>EASL:</b> Clinically significant portal hypertension (HVPG >10 mmHg) and Child-Pugh B are <u>absolute contraindications</u> to major resections (>2 segments).</li><li>- However, they are <u>not absolute contraindications</u> for limited resections, especially with minimally invasive surgery (MILS).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Minimally Invasive Surgery (MILS)</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Laparoscopic or robotic approaches should be favored over open surgery when feasible.</li><li>- MILS is associated with reduced blood loss, morbidity, and length of hospital stay.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>LR vs. Ablation for Small HCC (<2-3 cm)</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> For solitary HCC <2-3 cm, LR and thermal ablation offer comparable survival.</li><li>- <b>EASL:</b> LR is associated with higher morbidity than ablation. Ablation is preferred if a major hepatectomy would be required.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Liver Transplantation (LT)</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> LT is the optimal treatment for patients with early-stage HCC and decompensated cirrhosis or significant portal hypertension, as it cures both the cancer and the underlying liver disease.</li></ul>
                
        <details>
            <summary><strong>Selection Criteria</strong></summary>
            <div>
                <ul><li>- <b>Milan Criteria</b> (1 lesion ≤5 cm, or up to 3 lesions each ≤3 cm) is the standard, yielding 5-year survival rates approaching <q>80%</q>.</li><li>- <b>AASLD:</b> Discusses US-specific allocation (MMaT-3 MELD exception) and downstaging criteria (UNOS-DS).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Downstaging</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Patients with HCC beyond Milan criteria can be considered for LT after successful downstaging with locoregional therapies.</li><li>- <b>EASL:</b> AFP > <q>1,000 ng/ml</q> is an absolute contraindication to LT. Patients must be downstaged to AFP < <q>1,000 ng/ml</q> for at least 3 months before listing.</li><li>- <b>AASLD:</b> For UNOS exception, patients with baseline AFP ≥1000 ng/ml must have it fall below <q>500 ng/ml</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Bridging Therapy</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Locoregional therapy is recommended for patients on the waitlist for >6 months to reduce dropout risk.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Living Donor LT (LDLT)</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> LDLT is a viable alternative to deceased donor LT, especially where wait times are long. It reduces waitlist dropout risk.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Post-LT Recurrence</strong></summary>
            <div>
                <ul><li>- <b>AASLD:</b> Recurrence occurs in <q>10-15%</q> of patients post-LT. The <b>RETREAT score</b> can stratify 5-year recurrence risk from <q><3%</q> to <q>75%</q> based on explant pathology.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Adjuvant & Neoadjuvant Therapy</strong></summary>
            <div>
                <ul><li>- Aims to reduce the high risk of recurrence after resection/ablation (<q>50-70% at 5 years</q>).</li></ul>
                
        <details>
            <summary><strong>Neoadjuvant Therapy</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Neoadjuvant therapy is <u>not recommended</u> outside of clinical trials.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Adjuvant Therapy</strong></summary>
            <div>
                <ul><li>- <b>AASLD:</b> <u>Recommends</u> adjuvant <b>atezolizumab + bevacizumab</b> for high-risk patients after resection or ablation, based on the IMbrave050 trial which met its primary RFS endpoint (HR <q>0.72</q>).</li><li>- <b>EASL:</b> <u>Does not recommend</u> this combination, noting that in a later follow-up of IMbrave050, the RFS benefit was not sustained (updated HR <q>0.90</q>) and OS data was immature.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Locoregional Therapies</strong></summary>
            <div>
                <ul><li>- Includes percutaneous ablation, intra-arterial embolotherapies, and external beam radiation therapy (EBRT).</li><li>- Primarily used for BCLC Stage A (unresectable) and B patients.</li></ul>
                
        <details>
            <summary><strong>Ablative Therapies</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Thermal ablation (radiofrequency or microwave) is the treatment of choice for unresectable early-stage HCC (≤3 cm).</li></ul>
                
        <details>
            <summary><strong>Radiation Segmentectomy (SIRT) & EBRT as Ablative Alternatives</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> For tumors >3 cm or in locations difficult for thermal ablation (e.g., near large vessels, subdiaphragmatic), radiation segmentectomy or EBRT can be considered.</li><li>- <b>EASL:</b> Radiation segmentectomy with a dose > <q>190 Gy</q> achieved complete pathological necrosis in <q>67%</q> of cases.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Transarterial Embolotherapies (BCLC Stage B)</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> TACE is the standard primary option for BCLC Stage B.</li></ul>
                
        <details>
            <summary><strong>TACE Techniques</strong></summary>
            <div>
                <ul><li>- <b>EASL:</b> RCTs have not shown superiority of DEB-TACE over cTACE. Bland TAE is also a reasonable alternative to cTACE/DEB-TACE.</li><li>- <b>AASLD:</b> Conventional TACE and DEB-TACE have similar responses and safety profiles.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>TACE Refractoriness</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Patients not responding after 1-2 TACE sessions should be considered for other therapies (e.g., systemic therapy).</li><li>- Repeated TACE can lead to liver function deterioration (Child-Pugh A to B in <q>9-14%</q> of cases), precluding future systemic therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>TACE Unsuitable Patients</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Patients with extensive, diffuse, or infiltrative tumors (e.g., beyond Up-to-7 criteria) have poor outcomes with TACE and may be better suited for systemic therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>SIRT & EBRT for Intermediate/Advanced HCC</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> For patients with advanced stageHCC due to portal vein invasion, SIRT or EBRT are not recommended as alternatives to modern systemic immunotherapy combinations.</li></ul>
                
        <details>
            <summary><strong>SIRT vs. Systemic Therapy</strong></summary>
            <div>
                <ul><li>- <b>EASL:</b> Two major RCTs (SARAH, SIRveNIb) failed to show a survival benefit of SIRT over sorafenib.</li><li>- However, the DOSISPHERE-01 trial showed that <u>personalized dosimetry</u> (targeting >205 Gy to the lesion) significantly improved ORR (<q>71% vs 36%</q>) and OS (<q>26.6 vs 10.7 months</q>) compared to standard dosimetry.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>EBRT vs. Systemic Therapy</strong></summary>
            <div>
                <ul><li>- <b>EASL:</b> The NRG/RTOG1112 trial showed SBRT followed by sorafenib improved OS vs. sorafenib alone (median <q>15.8 vs 12.3 months</q>), though the result was borderline significant (p=<q>0.0554</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Combination of Locoregional + Systemic Therapy</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Combining TACE with TKIs (e.g., sorafenib) has <u>not shown a survival benefit</u> and is not recommended.</li></ul>
                
        <details>
            <summary><strong>TACE + Immunotherapy Combinations</strong></summary>
            <div>
                <ul><li>- <b>EASL:</b> Two recent Phase III trials showed a PFS benefit for adding immunotherapy combinations to TACE.</li><li>- <b>EMERALD-1:</b> TACE + Durvalumab + Bevacizumab ---> Median PFS <q>15.0 months</q> vs. 8.2 months for TACE alone (HR 0.77).</li><li>- <b>LEAP-012:</b> TACE + Pembrolizumab + Lenvatinib ---> Median PFS <q>14.6 months</q> vs. 10.0 months for TACE alone (HR 0.66).</li><li>- OS data for both trials are immature. A recommendation awaits final OS results.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Systemic Therapies</strong></summary>
            <div>
                <ul><li>- Reserved for advanced-stage HCC (BCLC C), TACE-unsuitable/refractory BCLC B, or progression after locoregional therapy.</li><li>- <b>Consensus:</b> Limited to patients with preserved liver function (<u>Child-Pugh A</u>) and good performance status (<u>ECOG 0-1</u>).</li></ul>
                
        <details>
            <summary><strong>First-Line Therapy</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> <b>Immunotherapy-based combinations</b> are the preferred first-line standard of care.</li></ul>
                
        <details>
            <summary><strong>Preferred Regimens</strong></summary>
            <div>
                <ul><li>- <b>Atezolizumab + Bevacizumab (IMbrave150):</b> Superior OS vs. sorafenib (median <q>19.2 vs 13.4 months</q>; HR 0.66).</li><li>- <b>AASLD:</b> Requires <u>EGD</u> before starting to manage variceal bleeding risk.</li><li>- <b>Durvalumab + Tremelimumab (STRIDE regimen; HIMALAYA):</b> Superior OS vs. sorafenib (median <q>16.4 vs 13.8 months</q>; HR 0.78).</li><li>- Notably improved long-term survival, with a 36-month survival rate of <q>30.7%</q> vs. 20.2% for sorafenib.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Alternative First-Line Options</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> For patients with contraindications to immunotherapy combinations (e.g., severe autoimmune disease, post-transplant), TKIs like <b>sorafenib</b> or <b>lenvatinib</b> are recommended.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Influence of Etiology</strong></summary>
            <div>
                <ul><li>- <b>EASL:</b> The choice of systemic therapy should <u>not</u> be influenced by the underlying liver disease etiology (HBV, HCV, non-viral), as subgroup analyses from trials have been inconsistent.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Second-Line Therapy & Beyond</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> There is no high-quality RCT data to guide second-line choices after progression on modern first-line immunotherapy combinations.</li></ul>
                
        <details>
            <summary><strong>AASLD Sequencing Guidance</strong></summary>
            <div>
                <ul><li>- <u>After Atezo+Bev:</u> Preferred agents are first-line TKIs (<b>sorafenib</b> or <b>lenvatinib</b>).</li><li>- <u>After Durva+Treme:</u> Preferred agents are first-line TKIs (<b>sorafenib</b> or <b>lenvatinib</b>).</li><li>- <u>After first-line TKI:</u> Preferred agents are <b>cabozantinib</b>, <b>regorafenib</b>, or <b>ramucirumab</b> (if AFP ≥400 ng/ml).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>EASL View</strong></summary>
            <div>
                <ul><li>- TKIs can be considered in selected patients after progression on ICI-based combinations.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Special Populations</strong></summary>
            <div>
                <ul><li>- Management in these groups requires careful consideration of risks and benefits.</li></ul>
                
        <details>
            <summary><strong>Child-Pugh B Cirrhosis</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> Systemic therapy is <u>not routinely recommended</u> due to poor outcomes and lack of trial data.</li><li>- May be considered in carefully selected patients (e.g., Child-Pugh B7) after multidisciplinary discussion.</li><li>- Median OS in this population is poor, typically <q>3.6 to 7.6 months</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Post-Transplant Recurrence</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> <b>ICIs are <u>NOT</u> recommended</b> due to a high risk of acute graft rejection (<q>~29%</q>) and associated mortality.</li><li>- Systemic therapy with TKIs (<b>sorafenib</b> or <b>lenvatinib</b>) can be considered.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment Management</strong></summary>
            <div>
                <ul><li>- Key questions regarding duration and continuation of therapy.</li></ul>
                
        <details>
            <summary><strong>Treatment Discontinuation</strong></summary>
            <div>
                <ul><li>- <b>EASL:</b> The consequences of stopping ICIs after a sustained response (e.g., after 2 years) are unknown. The decision can be made in discussion with the patient.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment Beyond Progression</strong></summary>
            <div>
                <ul><li>- <b>EASL:</b> In the absence of other options, a patient deriving clinical benefit may continue systemic therapy beyond radiological progression, as was allowed in pivotal trials.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Response Assessment & Clinical Trial Endpoints</strong></summary>
            <div>
                <ul><li>- Standardized criteria are essential for evaluating treatment efficacy in both clinical practice and research.</li></ul>
                
        <details>
            <summary><strong>Radiological Response Criteria</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> The choice of criteria depends on the treatment modality.</li></ul>
                
        <details>
            <summary><strong>Systemic Therapy</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> <b>RECIST v1.1</b> should be the primary method for assessing response in clinical trials.</li><li>- <b>mRECIST</b> can be used as a secondary assessment.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Locoregional Therapy</strong></summary>
            <div>
                <ul><li>- <b>AASLD:</b> <b>mRECIST</b> is the standard tool for assessing response after locoregional therapies as it evaluates viable, enhancing tumor.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinical Trial Endpoints</strong></summary>
            <div>
                <ul><li>- <b>Consensus:</b> <b>Overall Survival (OS)</b> should remain the primary endpoint for phase III RCTs in advanced HCC.</li></ul>
                
        <details>
            <summary><strong>Surrogacy of PFS</strong></summary>
            <div>
                <ul><li>- <b>EASL:</b> Progression-Free Survival (PFS) is <u>not a robust surrogate</u> for OS.</li><li>- The relationship is inconsistent across trials (e.g., HIMALAYA met OS but not PFS endpoint; COSMIC-312 met PFS but not OS).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Advance Care Planning (ACP) (AASLD)</strong></summary>
            <div>
                <ul><li>- <b>AASLD:</b> ACP should be offered to all patients receiving palliative-intent therapy or best supportive care.</li><li>- Facilitates shared decision-making, incorporates patient values, and can avoid unnecessary or futile treatments.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
